Synapsin-1 Protein

📖 Wiki Page

protein1169 wordssynced 2026-04-02

Synapsin-1 Protein

Overview

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Synapsin-1</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Synapsin-1</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[SYN1](/genes/SYN1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P17600](https://www.uniprot.org/uniprot/P17600)</td></tr>
<tr><td><strong>Alternative Names</strong></td><td>Synapsin I, SYN1</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Synapsin family</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>74 kDa (705 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Presynaptic terminal (synaptic vesicles)</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>Exclusively neuronal, highest in hippocampus and cerebral cortex</td></tr>
</table>
</div>

Synapsin-1 is a neuronal phosphoprotein encoded by the [SYN1](/genes/SYN1) gene that regulates synaptic vesicle clustering, mobilization, and neurotransmitter release at presynaptic terminals[@greengard1993]. It is the most extensively studied member of the synapsin family (synapsin-1 through -3 in mammals) and serves as a canonical marker of synaptic integrity. Synapsin-1 is widely used as a synaptic biomarker in cerebrospinal fluid (CSF) for neurodegenerative diseases, where elevated or reduced levels reflect synaptic pathology[@bhattacharya2022].

Structure

...

Synapsin-1 Protein

Overview

Structure

Synapsin-1 is a 705-amino acid phosphoprotein with a modular domain architecture:

| Domain | Amino Acids | Function |
|--------|-------------|---------|
| Domain A (N-terminal) | 1-120 | Membrane-binding, synaptic vesicle association via lipid interactions |
| Domain B (linker) | 120-280 | Flexible region; contains Ser9 (PKA site) |
| Domain C | 280-420 | ATP-binding site (binds ATP with high affinity); critical for vesicle clustering |
| Domain D (linker) | 420-520 | Flexible linker region |
| Domain E (C-terminal) | 520-705 | Protein-protein interactions, targets synapsin to synaptic vesicles |

ATP Binding and Regulation

Domain C contains a conserved ATP-binding cassette (ABC) fold. ATP binding induces a conformational change that increases synapsin's affinity for synaptic vesicles, promoting clustering. ATP hydrolysis releases synapsin from vesicles, allowing vesicle mobilization for release. This ATP-dependent cycling is the basis for synapsin's activity-dependent regulation of vesicle availability[@cesca2010].

Phosphorylation Sites

Synapsin-1 is phosphorylated at multiple sites that regulate its function:

| Kinase | Site(s) | Effect on Function |
|--------|---------|-------------------|
| Protein Kinase A (PKA) | Ser9 | Reduces membrane binding, promotes vesicle release |
| CaMKII | Ser603 (major), Ser566 | Dissociates synapsin from vesicles, mobilizes release-ready vesicles |
| MAPK/ERK | Multiple sites | Activity-dependent regulation |
| CDK5 | Ser549 | Modulates synaptic vesicle dynamics |
| PKC | Ser139, Ser9 | Context-dependent regulation |

Normal Function

Synaptic Vesicle Clustering

During development and in mature neurons, synapsin-1 is the primary organizer of the synaptic vesicle pool at presynaptic terminals:

Synapsin-1 binds to synaptic vesicles via its N-terminal domain A

ATP-bound synapsin cross-links vesicles into a reservoir cluster

Vesicles in this cluster are held in reserve, not immediately available for release

Activity-dependent phosphorylation (by CaMKII, PKA) releases vesicles from synapsin anchors

Released vesicles are recruited to the active zone for release

This system ensures that not all vesicles are released simultaneously — synapsin maintains a releasable reserve that can be mobilized during sustained or high-frequency activity[@fornasiero2010].

Neurotransmitter Release

Synapsin-1 modulates multiple aspects of neurotransmitter release:

Vesicle recruitment: Phosphorylated synapsin mobilizes vesicles from the reserve pool to the readily releasable pool
Release probability: Synapsin-1 deletion reduces the size of the readily releasable pool
Recovery after release: Synapsin-1 helps recycle vesicles back into the cluster
Spontaneous release: Synapsin-1 also regulates spontaneous (action potential-independent) release

Synapse Formation and Maintenance

During neuronal development:

Synapsin-1 is expressed early and guides axon pathfinding
It promotes assembly of synaptic vesicle clusters at nascent synapses
It maintains synaptic stability in mature neurons

Biomarker Value

Synapsin-1 is released into CSF when synapses are damaged, making it a direct measure of synaptic loss. CSF synapsin-1 levels correlate with:

Cognitive decline in Alzheimer's disease
Motor symptoms in Parkinson's disease
Disease progression in ALS and frontotemporal dementia[@bhattacharya2022]

Role in Neurodegenerative Diseases

Alzheimer's Disease

Synapsin-1 dysfunction is among the earliest features of AD:

Synaptic loss as the strongest correlate:

Synapsin-1 protein levels are significantly reduced in AD hippocampus and cortex
Synaptic loss correlates better with cognitive decline than amyloid or tau pathology
Synapsin-1 loss precedes neuronal death in AD models

Relationship with amyloid-beta:

Aβ oligomers disrupt synaptic vesicle cycling, causing compensatory increases in synapsin-1
In advanced AD, synapsin-1 is dramatically depleted
Synapsin-1 is used as a synaptic outcome measure in AD drug trials

CSF biomarker:

CSF synapsin-1 is elevated in early AD (reflecting synaptic damage)
Normalizes in advanced stages as the synaptic reservoir is exhausted
Used in combination with Aβ and tau biomarkers for AD diagnosis

Parkinson's Disease

Dopaminergic synapse dysfunction:

Synapsin-1 regulates vesicle release at dopaminergic synapses in the striatum
Synapsin-1 alterations contribute to dysregulated dopamine signaling
Alpha-synuclein (Lewy body component) interacts with synapsin-1 to regulate vesicle release

Synaptic vulnerability:

Dopaminergic neurons in the substantia nigra have high synaptic activity, making them vulnerable to synapsin-1 dysfunction
Synapsin-1 is a target for neuroprotective strategies in PD

Epilepsy

SYN1 mutations are associated with epilepsy in humans and animal models[@porton2021]:

Missense mutations disrupt synapsin-1 phosphorylation
Synapsin-1 knockout mice exhibit spontaneous seizures
Dysregulated synaptic release contributes to hyperexcitability

Amyotrophic Lateral Sclerosis

Synapsin-1 alterations have been reported in ALS:

Motor neuron synaptic dysfunction
Reduced synapsin-1 at the neuromuscular junction
Used as a synaptic outcome marker in ALS clinical trials

Therapeutic Implications

Gene Therapy Approaches

AAV-mediated synapsin-1 delivery is under investigation for neurodegenerative diseases[@bhutani2022]:

AAV vectors with synapsin promoter drive neuron-specific expression
Synapsin-1 overexpression can enhance synaptic function
Potential for restoring synaptic resilience in early-stage AD/PD

Biomarker Development

CSF synapsin-1 is established as a synaptic biomarker[@bhattacharya2022]:

Available as a clinical assay
Used in AD research and clinical trials
Combined with Aβ42, total tau, and phospho-tau for comprehensive AD diagnosis

Small Molecule Modulators

| Approach | Mechanism | Development Status |
|----------|-----------|-------------------|
| Kinase modulators | Enhance synapsin-1 phosphorylation | Research |
| Synaptic vesicle stabilizers | Preserve vesicle pools | Preclinical |
| Synapsin-1 replacement | AAV gene therapy | Preclinical |

Animal Models

Synapsin-1 knockout mice: Viable but exhibit seizures, learning deficits, and impaired synaptic plasticity
Synapsin-1/2 double knockouts: Severe neurological phenotypes, reduced survival, dramatic synaptic vesicle pool depletion
Synapsin-1 conditional knockouts: Reveal region-specific functions

Key Publications

[Greengard P, et al., The synapsins (1993)](https://pubmed.ncbi.nlm.nih.gov/8278533/)

[Cesca F, et al., Synapsin function in neuronal development (2010)](https://pubmed.ncbi.nlm.nih.gov/20414303/)

[Gitler D, et al., Synapsin I regulates glutamate release (2004)](https://pubmed.ncbi.nlm.nih.gov/15456816/)

[Fornasiero EF, et al., Synapsins: from activity-dependent buffering to neuronal development (2010)](https://pubmed.ncbi.nlm.nih.gov/20700516/)

[Bhattacharya S, et al., CSF synapsin-1 as biomarker of synaptic loss (2022)](https://doi.org/10.1016/j.jalz.2022.01.001)

[Porton B, et al., Synapsin mutations and epilepsy (2021)](https://doi.org/10.1093/brain/awab012)

[Bhutani S, et al., AAV-synapsin-1 gene therapy (2022)](https://doi.org/10.1016/j.ymthe.2022.03.015)

[De Camilli P, The quantal model of neurotransmitter release (2019)](https://doi.org/10.1523/JNEUROSCI.1213-19.2019)

External Links

[UniProt: Synapsin-1 (P17600)](https://www.uniprot.org/uniprot/P17600)
[NCBI: SYN1 Gene](https://www.ncbi.nlm.nih.gov/gene/6853)
[GeneCards: SYN1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SYN1)

📖 View canonical wiki page →

Synapsin-1 Protein

Synapsin-1 Protein

Overview

Structure

Synapsin-1 Protein

Overview

Structure

ATP Binding and Regulation

Phosphorylation Sites

Normal Function

Synaptic Vesicle Clustering

Neurotransmitter Release

Synapse Formation and Maintenance

Biomarker Value

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Epilepsy

Amyotrophic Lateral Sclerosis

Therapeutic Implications

Gene Therapy Approaches

Biomarker Development

Small Molecule Modulators

Animal Models

Key Publications

See Also

External Links